During the 8th annual Microbiome Movement Drug Development Europe, held in Barcelona (Spain), Microbiomepost conducted an exclusive interview with Elran Haber, CEO at Biomica Ltd, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics.
We discussed the emerging role of microbiome-based treatments in cancer care, an innovative and promising area of research.
There’s increasing evidence linking the human microbiome to various aspects of health, including immune system function, response to infections, and chronic diseases. In oncology, research has shown that the microbiome can influence the effectiveness of cancer treatments, such as chemotherapy and immunotherapy, and may play a role in the development and progression of cancer itself.
Few weeks ago, Biomica completes Phase I trial enrollment for a microbiome-based immuno-oncology drug, BMC128, an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbor specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes.
